The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
COPERNICUS uses a pragmatic study design to evaluate the efficacy and safety of subcutaneous amivantamab regimens combined with advancements in supportive care to prevent and proactively manage AEs in a diverse participant population. Supplementary file1 (MP4 117333 KB).
Authors
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Luis E. Raez (ORCID: https://orcid.org/0000-0003-2669-5771)
- Narjust Florez (ORCID: https://orcid.org/0009-0004-0806-6722)
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Joshua K. Sabari (ORCID: https://orcid.org/0000-0002-1556-1543)
- Andrew L. Johnson (ORCID: https://orcid.org/0000-0003-3848-6977)
- Paul Cifuentes (ORCID: https://orcid.org/0000-0001-9303-6819)
- Melissa L. Johnson (ORCID: https://orcid.org/0000-0001-9874-1314)
- Danny T. Nguyen
- Dennis Björk (ORCID: https://orcid.org/0009-0002-1568-2481)
- Farah Shanoon
- Balázs Halmos (ORCID: https://orcid.org/0000-0001-7548-8360)
- Yichuan Xia
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Denise D’Andrea
- Sarah Goldberg
- Ticiana Leal
- Nichelle Stigger
Institutions
- Albert Einstein College of Medicine (US)
- Emory Healthcare (US)
- Johnson & Johnson (United States) (US)
- Montefiore Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Yale University (US)
- NYU Langone Health (US)
- Samuel S. Fleisher Art Memorial (US)
- Sarah Cannon (US)
- Masaryk Memorial Cancer Institute (CZ)
- Dana-Farber Cancer Institute (US)
- LUNGevity Foundation (US)
- Tennessee Oncology (US)
- Hope Foundation (US)
- Winship Cancer Institute
- UC Davis Comprehensive Cancer Center
- University of California, Davis (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1007/s40487-025-00386-8
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52